Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on September 24, 2018, 10:33:56 am
-
Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a highly effective hepatitis C virus (HCV) treatment option for those whose previous direct-acting antiviral (DAA) regimen failed and who have evidence of resistance to certain hep C drug classes, MD Magazine reports.
Publishing their findings in the Journal of Hepatology, researchers conducted a study with 248 people whose hep C had not been cured by a prior DAA treatment for HCV and who had experience taking a medication in the NS5A inhibitor class.
For more...
https://www.hepmag.com/article/vosevi-beats-hepatitis-c-regardless-drug-resistance